<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00259116</url>
  </required_header>
  <id_info>
    <org_study_id>RLX.CHF.001</org_study_id>
    <nct_id>NCT00259116</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure</brief_title>
  <official_title>A Pilot Safety and Dose-Finding Trial of Intravenous Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies</source>
  <brief_summary>
    <textblock>
      This trial is a single center, open-label, dose-finding study of recombinant human relaxin
      (rhRlx) given intravenously (IV) to patients with stable, compensated CHF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Serial cohorts of patients with stable CHF will be enrolled upon meeting eligibility
      criteria. Dose escalation will be guided by hemodynamic response, safety and tolerability.
      The effects of rhRlx on hemodynamics will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac hemodynamics including PCWP, CO/CI, SVR</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
  </secondary_outcome>
  <enrollment>18</enrollment>
  <condition>Heart Failure, Congestive</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relaxin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients over the age of 18

          -  New York Heart Association (NYHA) Class II-III CHF

          -  Left Ventricular Ejection Fraction (LVEF) of &lt; 35%

        Exclusion Criteria:

          -  Acute coronary syndrome

          -  Acute decompensated CHF

          -  Hypotension

          -  Recent significant arrhythmia

          -  Recent stroke

          -  Significant renal or hepatic impairment

          -  Pregnancy or child-bearing potential
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam Teichman, MD</last_name>
    <role>Study Director</role>
    <affiliation>BAS Medical - Sponsor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite Hospital</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2005</study_first_submitted>
  <study_first_submitted_qc>November 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2005</study_first_posted>
  <last_update_submitted>April 13, 2009</last_update_submitted>
  <last_update_submitted_qc>April 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Sam Teichman, Chief Medical Officer</name_title>
    <organization>BAS Medical</organization>
  </responsible_party>
  <keyword>Congestive heart failure</keyword>
  <keyword>Relaxin</keyword>
  <keyword>Cardiac hemodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methocarbamol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

